|
TSHA Taysha Gene Therapies Inc 1806310 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-42,410,000.00 |
| Balance Sheet |
|
Current Assets
|
$282,250,000.00 |
|
Assets
|
$300,351,000.00 |
|
Current Liabilities
|
$20,098,000.00 |
|
Liabilities
|
$88,407,000.00 |
|
Equity
|
$211,944,000.00 |
|
Shares Out
|
287276885.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-40,878,000.00 |
|
Investing Cash Flow
|
$-3,024,000.00 |
| Market Analysis |
Market Cap
|
$1,689,188,083.80 |
|
Price
|
$5.71 |
|
BVPS
|
0.74 |
|
PB
|
7.95 |
|
EPS
|
-0.12 |
|
FCF
|
$-40,902,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:23 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:18 |
|
| Apr |
May |
Jun |
| 2026-03-19 |
-0.34 |
|
|
2026-05-06 |
-0.12 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-12 |
-0.09 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-04 |
-0.09 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view TSHA documents filed with the SEC.
TSHA Filings
Clear
